TILDRAKIZUMAB EFFICACY ON PSORIASIS IN PATIENTS WITH PSORIATIC ARTHRITIS-A 52-WEEK ANALYSIS FROM A PHASE 2 STUDY

被引:0
作者
Gottlieb, A. B. [1 ]
Ritchlin, C. T. [2 ]
Chou, R. C. [3 ]
Mendelsohn, A. M. [4 ]
Rozzo, S. [4 ]
Espinoza, L. [5 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Div Allergy Immunol & Rheumatol, Rochester, NY 14627 USA
[3] Univ Buffalo, Sch Med & Biomed Sci, Div Allergy Immunol & Rheumatol, Buffalo, NY USA
[4] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[5] LSU Hlth Sci Ctr, Sect Rheumatol, New Orleans, LA USA
关键词
D O I
10.1136/annrheumdis-2020-eular.778
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
SAT0417
引用
收藏
页码:1157 / 1158
页数:2
相关论文
共 2 条
  • [1] Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
    Reich, Kristian
    Papp, Kim A.
    Blauvelt, Andrew
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Nograles, Kristine
    Mehta, Anish
    Cichanowitz, Nicole
    Li, Qing
    Liu, Kenneth
    La Rosa, Carmen
    Green, Stuart
    Kimball, Alexa B.
    [J]. LANCET, 2017, 390 (10091) : 276 - 288
  • [2] Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
    Taylor, William
    Gladman, Dafna
    Helliwell, Philip
    Marchesoni, Antonio
    Mease, Philip
    Mielants, Herman
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (08): : 2665 - 2673